|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-8-3
|
|
pubmed:abstractText |
Activation of the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells by GLP-1 and exendin-4 increases insulin secretion. Exendin-4 is 39 amino acids long, unlike GLP-1 which has 30 amino acids. Because of its non-mammalian (lizard) origin and unique C-terminal sequence, exendin-4 may be immunogenic in humans. We showed previously that the C terminally truncated exendin peptide exendin (1-30) has a reduced affinity for the GLP-1 receptor and a diminished ability to increase intracellular cAMP in insulinoma cells. Here we show that daily intraperitoneal injection of exendin (1-30) (1 nmol/kg) for 20 d followed by 31 d twice daily to Lepr(db)/Lepr(db) (db/db) mice significantly reduced the amount of visceral fat relative to saline-treated controls and improved HbA1C (control 9.5 +/- 0.2% vs treated 7.9 +/- 0.2%, p = 0.001) but was not as effective as exendin-4. To examine the ability of exendin (1-30) to stimulate beta-cell growth, we injected one group of 3-mo-old Fisher rats with exendin (1-30) (1 nmol/kg) and another group with saline for 8 d. We observed no change in beta-cell area, but did see a change in the number of islets with nuclei positive for BrdU [10.7 +/- 1.8% exendin (1-30) vs 6.5 +/- 0.5% control].
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1355-008X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16077164-Adipose Tissue,
pubmed-meshheading:16077164-Amino Acid Sequence,
pubmed-meshheading:16077164-Animals,
pubmed-meshheading:16077164-Blood Glucose,
pubmed-meshheading:16077164-Body Composition,
pubmed-meshheading:16077164-Bromodeoxyuridine,
pubmed-meshheading:16077164-Cell Proliferation,
pubmed-meshheading:16077164-Diabetes Mellitus,
pubmed-meshheading:16077164-Eating,
pubmed-meshheading:16077164-Hemoglobin A, Glycosylated,
pubmed-meshheading:16077164-Immunoenzyme Techniques,
pubmed-meshheading:16077164-Injections, Intraperitoneal,
pubmed-meshheading:16077164-Insulin,
pubmed-meshheading:16077164-Islets of Langerhans,
pubmed-meshheading:16077164-Magnetic Resonance Imaging,
pubmed-meshheading:16077164-Mice,
pubmed-meshheading:16077164-Mice, Inbred C57BL,
pubmed-meshheading:16077164-Mice, Inbred Strains,
pubmed-meshheading:16077164-Microscopy, Confocal,
pubmed-meshheading:16077164-Molecular Sequence Data,
pubmed-meshheading:16077164-Peptides,
pubmed-meshheading:16077164-Rats,
pubmed-meshheading:16077164-Rats, Inbred F344,
pubmed-meshheading:16077164-Venoms,
pubmed-meshheading:16077164-Weight Gain
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
In vivo biological activity of exendin (1-30).
|
|
pubmed:affiliation |
Diabetes Section National Institute on Aging, National Institutes of Health. Diabetes Section, National Institute on Aging, National Institutes of Health, Baltimore MD 21224, USA. medoyle@dental.ufl.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, N.I.H., Extramural
|
